| Prostate Cancer, Version 2.2019 |
191 |
| Rectal Cancer, Version 2.2018 Clinical Practice Guidelines in Oncology |
141 |
| NCCN Guidelines (R) Insights Non- Small Cell Lung Cancer, Version 5.2018 Featured Updates to the NCCN Guidelines |
128 |
| NCCN Guidelines (R) Insights Colon Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines |
120 |
| Cervical Cancer, Version 3.2019 |
119 |
| Soft Tissue Sarcoma, Version 2.2018 |
105 |
| NCCN Guidelines (R) Insights Head and Neck Cancers, Version 1.2018 Featured Updates to the NCCN Guidelines |
86 |
| Uterine Neoplasms, Version 1.2018 Clinical Practice Guidelines in Oncology |
85 |
| Management of Immunotherapy-Related Toxicities. Version 1.2019 |
82 |
| Non-Small Cell Lung Cancer, Version 1.2020 Featured Updates to the NCCN Guidelines |
76 |
| Cutaneous Melanoma Version 2.2019 |
75 |
| Acute Myeloid Leukemia, Version 3.2019 |
71 |
| Breast Cancer, Version 4.2017 Clinical Practice Guidelines in Oncology |
63 |
| Lung Cancer Screening, Version 3.2018 |
60 |
| NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection |
59 |
| Esophageal and Esophagogastric Junction Cancers, Version 2.2019 |
59 |
| Chronic Myeloid Leukemia, Version 1.2019 Clinical Practice Guidelines in Oncology |
57 |
| NCCN Guidelines (R) Insights Bladder Cancer, Version 5.2018 Featured Updates to the NCCN Guidelines |
55 |
| NCCN Guidelines (R) Insights Neuroendocrine and Adrenal Tumors, Version 2.2018 Featured Updates to the NCCN Guidelines |
53 |
| Breast Cancer, Version 3.2018 Featured Updates to the NCCN Guidelines |
50 |
| Cancer-Associated Venous Thromboembolic Disease, Version 2.2018 Featured Updates to the NCCN Guidelines |
46 |
| Breast Cancer Screening and Diagnosis, Version 3.2018 |
45 |
| Hepatobiliary Cancers, Version 2.2019 Featured Updates to the NCCN Guidelines |
44 |
| NCCN Guidelines (R) Insights Thyroid Carcinoma, Version 2.2018 Featured Updates to the NCCN Guidelines |
40 |
| NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019 |
36 |
| NCCN Guidelines (R) Insights Small Cell Lung Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines |
36 |
| NCCN Guidelines Updates: Pancreatic Cancer |
35 |
| NCCN Guidelines (R) Insights Colorectal Cancer Screening, Version 1.2018 Featured Updates to the NCCN Guidelines |
31 |
| NCCN Guidelines Updates: Breast Cancer |
30 |
| Distress Management, Version 3.2019 |
29 |
| Merkel Cell Carcinoma, Version 1.2018 Clinical Practice Guidelines in Oncology |
29 |
| Survivorship, Version 2.2018 Clinical Practice Guidelines in Oncology |
28 |
| Kidney Cancer, Version 2.2020 Featured Updates to the NCCN Guidelines |
28 |
| Adolescent and Young Adult Oncology, Version 2.2018 |
25 |
| Adult Cancer Pain, Version 3.2019 |
25 |
| Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019 Featured Updates to the NCCN Guidelines |
24 |
| Anal Carcinoma, Version 2.2018 |
24 |
| NCCN Guidelines (R) Insights Multiple Myeloma, Version 3.2018 Featured Updates to the NCCN Guidelines |
23 |
| Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors |
22 |
| New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity |
22 |
| Multiple Myeloma, Version 1.2020 Featured Updates to the NCCN Guidelines |
21 |
| A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events |
21 |
| B-Cell Lymphomas, Version 3.2019 Featured Updates to the NCCN Guidelines |
20 |
| NCCN Guidelines Updates: New Immunotherapy Strategies for Improving Outcomes in Non-Small Cell Lung Cancer |
17 |
| Community Oncologists' Decision-Making for Treatment of Older Patients With Cancer |
16 |
| NCCN Guidelines Updates: Management of Prostate Cancer |
16 |
| NCCN Guidelines Updates: Management of Metastatic Kidney Cancer |
15 |
| Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma |
15 |
| NCCN Guidelines (R) Insights Hodgkin Lymphoma, Version 1.2018 Featured Updates to the NCCN Guidelines |
15 |
| Financial Burdens of Cancer Treatment: A Systematic Review of Risk Factors and Outcomes |
14 |
